bb3497 has been researched along with actinonin in 5 studies
| Studies (bb3497) | Trials (bb3497) | Recent Studies (post-2010) (bb3497) | Studies (actinonin) | Trials (actinonin) | Recent Studies (post-2010) (actinonin) |
|---|---|---|---|---|---|
| 13 | 0 | 2 | 166 | 0 | 57 |
| Protein | Taxonomy | bb3497 (IC50) | actinonin (IC50) |
|---|---|---|---|
| Urokinase-type plasminogen activator | Homo sapiens (human) | 0.14 | |
| Interstitial collagenase | Homo sapiens (human) | 1.1 | |
| Neprilysin | Oryctolagus cuniculus (rabbit) | 8.2 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 3 | |
| Stromelysin-1 | Homo sapiens (human) | 6 | |
| Neprilysin | Homo sapiens (human) | 6.7 | |
| Aminopeptidase N | Homo sapiens (human) | 0.4 | |
| Peptide deformylase | Staphylococcus aureus subsp. aureus Mu50 | 0.005 | |
| Peptide deformylase | Staphylococcus aureus | 0.02 | |
| Peptide deformylase 1A, chloroplastic/mitochondrial | Arabidopsis thaliana (thale cress) | 0.027 | |
| Peptide deformylase, mitochondrial | Homo sapiens (human) | 0.5622 | |
| Peptide deformylase | Escherichia coli | 0.052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckett, RP; Davies, SJ; Launchbury, SB; Miller, A; Pratt, LM; Spavold, ZM; Todd, RS; Whittaker, M | 1 |
| Canaan, S; Cavalier, JF; Magrioti, V; Mallick, I; Mavrikaki, V; Pagonis, A; Poncin, I | 1 |
| Baker, PJ; Barynin, V; Beckett, RP; Brown, A; Catlin, G; Clements, JM; Hunter, MG; Lobell, M; Palan, S; Rice, DW; Rodgers, HF; Salama, S; Thomas, W; Whittaker, M; Wood, S | 1 |
| Kanwar, AJ; Khuller, GK; Sharma, A; Sharma, S | 2 |
5 other study(ies) available for bb3497 and actinonin
| Article | Year |
|---|---|
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.
Topics: Amidohydrolases; Aminopeptidases; Anti-Bacterial Agents; Crystallography, X-Ray; Enzyme Inhibitors; Hydroxamic Acids; Molecular Conformation; Structure-Activity Relationship | 2001 |
Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives.
Topics: Animals; Anti-Bacterial Agents; Hydrazines; Hydroxamic Acids; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Structure-Activity Relationship | 2022 |
Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.
Topics: Amidohydrolases; Aminopeptidases; Animals; Anti-Bacterial Agents; Crystallography, X-Ray; Drug Resistance, Microbial; Enzyme Inhibitors; Escherichia coli; Hydroxamic Acids; Microbial Sensitivity Tests; Mutation; Rats; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2001 |
In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
Topics: Amidohydrolases; Animals; Antibiotics, Antitubercular; Dipeptides; Drug Synergism; Drug Therapy, Combination; Hydroxamic Acids; Hydroxylamine; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Phenanthrolines; Protease Inhibitors; Rifampin; Tuberculosis | 2009 |
Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
Topics: Amidohydrolases; Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Enzyme Inhibitors; Hydroxamic Acids; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 2010 |